Aridis Pharmaceuticals, Inc.
ARDS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | 0.09 | 0.02 |
| FCF Yield | -131.83% | -81.94% | -37.45% | -22.14% |
| EV / EBITDA | -0.79 | -0.33 | -2.18 | -0.58 |
| Quality | ||||
| ROIC | 174.87% | 1,240.23% | 400.09% | -270.17% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.96 | 0.54 | 0.92 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -28.68% | 5.92% |
| Free Cash Flow Growth | -24.47% | -12.58% | -150.13% | 66.60% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | 0.32 | 0.34 | 0.73 |
| Interest Coverage | -79.35 | 178.41 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 134.32 | 147.50 |